Novo Nordisk Ltd
Novo Nordisk was founded in 1923 out of a passion to help people with diabetes. With our strong commitment to patients and by offering the greatest portfolio of products in the industry, we look to defeat diabetes by improving: awareness, prevention, detection, and treatment of this chronic disease. In addition, Novo Nordisk holds a leading position within the areas of haemostasis management, growth hormone therapy and hormone replacement therapy.
However, we also believe that it is important to change the future of diabetes. Here at Novo Nordisk, we want to play a key part in that change and so have put into place a number of initiatives that we contribute to and collaborate with others on.
Setting up the Novo Nordisk Research Foundation over ten years ago has allowed us to support UK Healthcare Professionals in clinical projects investigating both the causes and future treatment of diabetes. In recognition of the fact that diabetes is a global epidemic, the World Diabetes Foundation (WDF) was also established in 2002 to support the prevention and treatment of diabetes in the developing world.
We have also supported a number of other projects both at home and overseas. Providing financial assistance to support “The Oxford Centre for Diabetes, Endocrinology and Metabolism”, has gone some way to achieve the Oxford Vision 2020. In 2008 a five year programme named ‘Changing Diabetes® in Children’ was launched with the aim of reducing child mortality in sub-Saharan Africa and saving 10,000 children by 2015.
Novo Nordisk remains committed to its employees as well as the communities that we all live and work in. Governed by its Triple Bottom Line approach to business, Novo Nordisk is not only focussed on superior business results but also in acting in an environmentally and socially responsible manner.